ClinVar Miner

Submissions for variant NM_000546.5(TP53):c.478A>G (p.Met160Val) (rs377274728)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories RCV000513585 SCV000884717 uncertain significance not provided 2017-08-10 criteria provided, single submitter clinical testing The TP53 c.478A>G;p.Met160Val variant has not been described in the medical literature as a germline variant occurring in an individual with Li-Fraumeni syndrome. The variant has been described as a somatic variant occurring in multiple different tumors (Glebov 1994, Powell 2000, Yokoyama 1998). The variant is not listed in the ClinVar database, but is listed in the dbSNP variant database (rs377274728) with an allele frequency of 0.0004063 percent (1/246128 alleles) in the Genome Aggregation Database. The amino acid at this position is moderately conserved across species, is reported to occur in a DNA binding domain, and has been reported to not function normally in at least one assay (Shiraishi 2004). However, computational algorithms (AlignGVGD, PolyPhen2, SIFT) predict this variant is tolerated. Considering available information, there is not enough evidence to classify this variant with certainty. References: Glebov OK et al. Frequent p53 gene mutations and novel alleles in familial breast cancer. Cancer Res. 1994 Jul 15;54(14):3703-9. Powell B et al. Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer. Clin Cancer Res. 2000 Feb;6(2):443-51. Shi XB et al. A modified yeast assay used on archival samples of localized prostate cancer tissue improves the detection of p53 abnormalities and increases their predictive value. BJU Int. 2004 Nov;94(7):996-1002. Shiraishi K et al. Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library. J Biol Chem. 2004 Jan 2;279(1):348-55. Yokoyama N et al. Mutations of p53 in gallbladder carcinomas in high-incidence areas of Japan and Chile. Cancer Epidemiol Biomarkers Prev. 1998 Apr;7(4):297-301.
Ambry Genetics RCV000570720 SCV000672404 likely benign Hereditary cancer-predisposing syndrome 2016-10-12 criteria provided, single submitter clinical testing Lines of evidence used in support of classification: In silico models in agreement (benign),Other data supporting benign classification
CeGaT Praxis fuer Humangenetik Tuebingen RCV000513585 SCV000608803 uncertain significance not provided 2017-06-30 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.